Last reviewed · How we verify
Dexmeditomedine
Dexmeditomedine is a Small molecule drug developed by National Cancer Institute, Egypt. It is currently FDA-approved. Also known as: Dexmedetomidine at 0.6 mcg/kg/hr then 0.2 to 1 mcg/kg/hr..
At a glance
| Generic name | Dexmeditomedine |
|---|---|
| Also known as | Dexmedetomidine at 0.6 mcg/kg/hr then 0.2 to 1 mcg/kg/hr. |
| Sponsor | National Cancer Institute, Egypt |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- The Effect of Ketamine - Dexmedetomidine Admixture (Ketodex) on Hemodynamic Stability During Anesthesia Induction in Adults. (PHASE4)
- Comparative Study Between Dexmedetomidine & Neostigmine as an Adjuvant to Local Anesthetic Mixture in Peribulbar Block in Vitreoretinal Surgeries (EARLY_PHASE1)
- Dexmeditomedine as an Adjuvant to Levobupivacaine in Transversus Thoracis Plane Block on the Management of Post-sternotomy Pain in Open-heart Surgeries (NA)
- Dexmeditomedine Versus No Sedation in Management of Agitation in COPD Patients Receiving Noninvasive Ventilation
- Effect of Opioid Free Versus Opioid-Based Anesthesia on Cerebral Oximetry In Gastric Sleeve Operation (NA)
- Intrathecal Versus Intravenous Dexmeditomedine in Transurethral Resection of the Prostate (PHASE4)
- Comparative Study of Ropivacaine and Ropivacaine With Dexmeditomedine in TAP Blocks (NA)
- Dexmedetomidine for Sedation During Radiological Interventional Procedures (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dexmeditomedine CI brief — competitive landscape report
- Dexmeditomedine updates RSS · CI watch RSS
- National Cancer Institute, Egypt portfolio CI
Frequently asked questions about Dexmeditomedine
What is Dexmeditomedine?
Dexmeditomedine is a Small molecule drug developed by National Cancer Institute, Egypt.
Who makes Dexmeditomedine?
Dexmeditomedine is developed and marketed by National Cancer Institute, Egypt (see full National Cancer Institute, Egypt pipeline at /company/national-cancer-institute-egypt).
Is Dexmeditomedine also known as anything else?
Dexmeditomedine is also known as Dexmedetomidine at 0.6 mcg/kg/hr then 0.2 to 1 mcg/kg/hr..
What development phase is Dexmeditomedine in?
Dexmeditomedine is FDA-approved (marketed).
Related
- Manufacturer: National Cancer Institute, Egypt — full pipeline
- Therapeutic area: All drugs in Other
- Also known as: Dexmedetomidine at 0.6 mcg/kg/hr then 0.2 to 1 mcg/kg/hr.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing